ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3% – Should You Sell?

ImmunityBio, Inc. (NASDAQ:IBRX) was down 5.3% during mid-day trading on Thursday . The stock traded as low as $7.27 and last traded at $7.3650. Approximately 4,562,757 shares were traded during trading, a decline of 87% from the average daily volume of 35,245,004 shares. The stock had previously closed at $7.78.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Bullish coverage highlighting growth and platform opportunity — recent pieces point to ImmunityBio’s aggressive global expansion and argue the company’s platform could support upside beyond Anktiva, which may attract buyers and support a rally. ImmunityBio (IBRX) Global Expansion Bolsters 266% Jump This Year
• Positive Sentiment: Long‑term narrative/analysis argues platform value beyond current headline product — a detailed Seeking Alpha piece reframes ImmuityBio as a platform play, which can support investor interest despite short‑term regulatory headlines. Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva
• Neutral Sentiment: Procedural investor outreach and lead‑plaintiff deadlines — multiple law firms and investor‑rights groups are reminding affected shareholders of the May 26, 2026 deadline to seek lead‑plaintiff status in the pending securities actions; procedural but increases class consolidation activity. Deadline to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 – Contact Kaplan Fox
• Negative Sentiment: FDA warning letter cited as trigger for securities litigation — Hagens Berman and others report that an FDA letter flagged allegedly misleading efficacy claims by the company’s chairman about Anktiva; the firm says this drove a multi‑billion dollar market‑cap swing and sparked a securities class action. That regulatory finding materially increases legal and reputational risk. IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims…
• Negative Sentiment: Multiple class actions and investigations piling up — several firms (Kessler Topaz, Bragar Eagel & Squire, Lowey Dannenberg, Robbins Geller, Pomerantz, Faruqi, Rosen, etc.) have filed suits or launched investigations alleging material misstatements/omissions about Anktiva; consolidated litigation or large settlements could be a financial and distraction risk. ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. BTIG Research initiated coverage on ImmunityBio in a research note on Thursday, March 12th. They set a “buy” rating and a $13.00 target price for the company. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a research report on Wednesday, April 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $12.00 target price (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, ImmunityBio currently has a consensus rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Stock Up 6.2%

The company has a 50 day moving average price of $8.00 and a 200-day moving average price of $4.71. The company has a market cap of $7.92 billion, a price-to-earnings ratio of -20.26 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. On average, analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Activity

In related news, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total value of $250,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Barry J. Simon sold 165,000 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the sale, the director directly owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. This represents a 5.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 451,967 shares of company stock worth $4,216,412 over the last ninety days. Company insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Several large investors have recently modified their holdings of the company. Wealth Management Partners LLC lifted its holdings in ImmunityBio by 56.3% in the first quarter. Wealth Management Partners LLC now owns 39,860 shares of the company’s stock valued at $306,000 after buying an additional 14,360 shares during the period. Walser Wealth Management Company A Ltd Liability Co bought a new position in shares of ImmunityBio in the 4th quarter worth about $59,000. Invesco Ltd. lifted its stake in shares of ImmunityBio by 14.6% in the 4th quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock valued at $362,000 after purchasing an additional 23,353 shares during the period. Corient Private Wealth LLC boosted its position in shares of ImmunityBio by 69.7% during the 4th quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock valued at $660,000 after purchasing an additional 136,858 shares in the last quarter. Finally, EP Wealth Advisors LLC acquired a new stake in ImmunityBio during the fourth quarter worth approximately $35,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.